AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03828227
Drug: OPTIMOX-bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus
Trial: NCT03828227
Drug: Capecitabine plus bevacizumab
RxNorm normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w).
Trial: NCT02400619
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin type A Botox
Trial: NCT00168155
Drug: perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04008888
Drug: Melphalan Given IV
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
Trial: NCT04008888
Drug: Fludarabine Injection
RxNorm normalized name: fludarabine Injection
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
Trial: NCT04008888
Drug: PI and dexamethasone as maintenance therapy
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
Trial: NCT04008888
Drug: PI+IMids+Dexamethasone as Consolidated Chemotherapy
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
Trial: NCT03046953
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-PDL1 antibody
Trial: NCT01199887
Drug: IW001
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
Trial: NCT02924233
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
Trial: NCT00023738
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023738
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023738
Drug: semaxanib
RxNorm normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00200577
Drug: TIL + IL2
RxNorm normalized name: DAB(SUB 389)IL2
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
Trial: NCT00229749
Drug: AVI-4065 Injection
RxNorm normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01712139
Drug: Irbesartan and Hydrochlorothiazide
RxNorm normalized name: Irbesartan and Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01712139
Drug: Avalide
RxNorm normalized name: Avalide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00656175
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir
Trial: NCT02723448
Drug: aclarubicin
RxNorm normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
Trial: NCT00100347
Drug: PPI-2458
RxNorm normalized name: PPI-2458
DrugBank: PPI-2458 (DB05864)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02385110
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks.
Trial: NCT02385110
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide.
Trial: NCT02385110
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks.
Trial: NCT02385110
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
Trial: NCT03934840
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 Q 21 days
Trial: NCT03934840
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 4 Q21 Days x 6 cycles with ADT
Trial: NCT03934840
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg PO daily
Trial: NCT03934840
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg PO daily on chemotherapy completion
Trial: NCT04526665
Drug: Elafibranor 80mg
RxNorm normalized name: ELAFIBRANOR 80MG TAB
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor 80mg daily
Trial: NCT01863615
Drug: Isotretinoin 40 mg
RxNorm normalized name: isotretinoin 40 MG
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Roaccutan 2 capsules of 20 mg; reference drug
Trial: NCT01863615
Drug: Isotretinoin 40 mg
RxNorm normalized name: isotretinoin 40 MG
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oratane 2 capsules of 20 mg; test drug
Trial: NCT02494895
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
Trial: NCT02494895
Drug: Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
Trial: NCT02587195
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00275665
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02749227
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
Trial: NCT02364583
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
Trial: NCT01360788
Drug: Combination ipratropium/salbutamol or placebo (nebulization)
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
Trial: NCT01646840
Drug: PF-04958242 capsule
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PF-04958242 0.35 mg oral capsule
Trial: NCT01646840
Drug: PF-04958242 oral solution
RxNorm normalized name: taurine
DrugBank: PF-04958242 (DB11843)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of PF-04958242 0.35 mg oral solution
Trial: NCT02136901
Drug: Intra-Articular Injections with Hyaluronic Acid (HA)
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Trial: NCT02714205
Drug: transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
Trial: NCT01465230
Drug: Maintenance lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily maintenance treatment, oral lenalidomide
Trial: NCT00905567
Drug: Topiramate 2 x 25 mg tablet
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02676739
Drug: Adderall XR
RxNorm normalized name: Adderall XR
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03770338
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20ug dosage daily injection, 1-month preoperative
Trial: NCT02753816
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03017391
Drug: metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
Trial: NCT03017391
Drug: granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: granisetron patch 3.1mg/24 hours, use until toxicity
Trial: NCT03017391
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 8 mg, last step in both algorithms
Trial: NCT03017391
Drug: Granisetron 2Mg Tablet
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: granisetron 2 mg loading dose
Trial: NCT04346407
Drug: Dronabinol 2.5mg Cap
RxNorm normalized name: DRONABINOL 2.5MG CAP
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
Trial: NCT02337634
Drug: Milk Thistle
RxNorm normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Trial: NCT00484926
Drug: Aspirin monotherapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: stopping clopidogrel at 1 year after DES
Trial: NCT00484926
Drug: Aspirin,Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: continue aspirin and clopidogrel 1year after DES
Trial: NCT01005784
Drug: Cetrorelix (Cetrotide)
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flexible antagonist administration according to specified criteria
Trial: NCT01005784
Drug: Cetrorelix (Cetrotide)
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fixed antagonist administration on day 6 of ovarian stimulation
Trial: NCT02812641
Drug: BPF-CCRT (run-in)
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
Trial: NCT02812641
Drug: BPF-CCRT (randomized)
RxNorm normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-two patients will be planned to assign to the experimental arm
Trial: NCT02812641
Drug: PF-CCRT (randomized)
RxNorm normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-two patients will be planned to assign to the active control arm
Trial: NCT00828061
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
Trial: NCT00828061
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
Trial: NCT00408551
Drug: floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00408551
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00408551
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04252963
Drug: MUCOLASE tablet (streptokinase • streptodornase)
RxNorm normalized name: streptodornase / streptokinase
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: streptokinase • streptodornase 5mg
Trial: NCT01597297
Drug: BIIB041 (PR Fampridine)
RxNorm normalized name: FAMPRIDINE
DrugBank: BIIB021 (DB12359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Trial: NCT02465437
Drug: JBT-101
RxNorm normalized name: JBT-101
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
Trial: NCT00571103
Drug: acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 333mg tablets taken three times daily.
Trial: NCT00540644
Drug: lenalidomide (Revlimid®)
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg p.o. daily on days 1-21 of each 28 day cycle
Trial: NCT00540644
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg p.o. Q.O.D.
Trial: NCT01369745
Drug: dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dipyridamole 360 mg daily
Trial: NCT01369745
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg daily
Trial: NCT01369745
Drug: Z102
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 2.7 mg plus dipyridamole 360 mg daily
Trial: NCT02163681
Drug: Hyperpolarized Helium-3 MRI of the chest
RxNorm normalized name: Helium
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
Trial: NCT01067417
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Trial: NCT01073826
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01073826
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00563914
Drug: amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: associated with artesunate
Trial: NCT04425681
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment of LM With osimertinb
Trial: NCT04425681
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment of LM With Bevacizumab
Trial: NCT02862938
Drug: NT-501 ECT implant
RxNorm normalized name: NT 501
DrugBank: Ciliary neurotrophic factor (DB05344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
Trial: NCT02768792
Drug: pembrolizumab,
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
Trial: NCT00225186
Drug: Visanne (SH T00660AA , BAY86-5258)
RxNorm normalized name: Glutathione-SH
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
Trial: NCT00558298
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00552708
Drug: COREG CR
RxNorm normalized name: Coreg CR
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00552708
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00441870
Drug: 99mTC-EC20 (Folic acid-technetium 99m conjugate)
RxNorm normalized name: linoleic acids, conjugated
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
Trial: NCT01537380
Drug: Cefazoline
RxNorm normalized name: Cefazoline
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
Trial: NCT03173456
Drug: oxycodone/APAP
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen 5 mg-325 mg oral tablet
Trial: NCT03173456
Drug: hydrocodone/APAP
RxNorm normalized name: HYDROCODONE BITARTRATE 5 mg / ACETAMINOPHEN 325 mg ORAL TABLET [HYDROCODONE/APAP]
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet